EU4HEALTH

EU4Health has three main areas of focus.

Area 1 is responding to the COVID-19 crisis, which aims to ensure that Europe is better equipped to deal with future health crises.

Area 2 is resilience to cross-border health threats, which aims to improve preparedness for and response to health emergencies that may have a cross-border impact.

Area 3 is Europe's beating cancer plan, which aims to improve cancer prevention, diagnosis, treatment, and care across Europe.

EU4HEALTH also has a pharmaceutical strategy that aims to ensure access to affordable and innovative medicines for all Europeans. It also covers areas such as health system digitalization, reducing resistant infections, and improving vaccination. 

Who is it for? 

EU4HEALTH targets:

• Academia
• Education establishments
• Research institutes
• Hospitals
• Public health authorities and more. 

Potential organizations for collaboration are: health organizations, non-governmental organizations, private sector entities, universities, and other organizations from EU member states, third countries associated with EU4HEALTH, those listed in the annual work program or an international organization.

How to apply

Applications must be submitted through the official Funding and Tenders Portal, and organizations must be registered in the Participant Register.

See the official UiB Guide to EU application for more details 

Financing level

EU4HEALTH cofincances projects, meaning they provide 60% of project cost unless otherwise specified in the call. If the project is deemed to be of exceptional utility, the EU contribution can be up to 80% of project costs. 

Exceptional utility is clearly defined as at least 30 % of the budget of the proposal being allocated to Member States whose GNI per inhabitant is less than 90 % of the Union average and if organizations from at least 14 participating Member States participate in the action, of which at least four are Member States whose GNI per inhabitant is less than 90 % of the Union average. 

Joint Actions

Norwegian health authorities participate in several Joint Actions over the next three years.

The Norwegian Medicines Agency will take part in two Joint Actions, on medicine shortages and safety assessments for clinical studies. The Norwegian Institute of Public Health will participate in a Joint Action to develop better, integrated systems for monitoring infectious diseases, and the Norwegian Directorate of Health will participate in two Joint Actions – one on the transfer of best practices in the primary health care service and one on health personnel planning.

Contact your local advisor or the Research and Innovation Department (FIA) for questions